DR. MIHAEL H POLYMEROPOULOS, MD
Psychiatric at Ridge Mist Ter, Rockville, MD
License number
Maryland D0052719
Category
Psychiatric
Type
Psychiatry
Address
Address
11300 Ridge Mist Ter, Rockville, MD 20854
Phone
(240) 599-4500
Personal information
See more information about MIHAEL H POLYMEROPOULOS at radaris.comName
Address
Phone
10627 Rivers Bend Ln, Potomac, MD 20854
11300 Ridge Mist Ter, Potomac, MD 20854
3801 Raymond Ln, Rockville, MD 20854
4977 Battery Ln #420, Bethesda, MD 20814
8301 Raymond Ln, Potomac, MD 20854
Professional information
See more information about MIHAEL H POLYMEROPOULOS at trustoria.com
Genes Expressed In Breast Cancer As Prognostic And Therapeutic Targets
Genes Expressed In Breast Cancer As Prognostic And Therapeutic Targets
US Patent:
2003006, Apr 3, 2003
Filed:
Apr 11, 2002
Appl. No.:
10/120583
Inventors:
Marlene Dressman - Germantown MD, US
Christian Lavedan - Potomac MD, US
Mihael Polymeropoulos - Potomac MD, US
Christian Lavedan - Potomac MD, US
Mihael Polymeropoulos - Potomac MD, US
International Classification:
C12Q001/68
US Classification:
435/006000, 702/020000
Abstract:
Methods are disclosed for, determining the endocrine responsiveness of breast carcinoma and treating and monitoring the progression of breast carcinoma based on genes which are differentially expressed in breast tumors. Also disclosed are methods for identifying agents useful in the treatment of breast carcinoma, methods for monitoring the efficacy of a treatment for breast carcinoma, methods for inhibiting the proliferation of a breast carcinoma, and breast-specific vectors including the promoters of the disclosed genes.
Eleven Highly Informative Microsatelite Repeat Polymorphic Dna Markers
Eleven Highly Informative Microsatelite Repeat Polymorphic Dna Markers
US Patent:
5861504, Jan 19, 1999
Filed:
Sep 28, 1992
Appl. No.:
7/952277
Inventors:
Mihael H. Polymeropoulos - Potomac MD
Carl R. Merril - Rockville MD
Carl R. Merril - Rockville MD
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
and Human Services - Washington DC
International Classification:
C07H 2104
US Classification:
536 2433
Abstract:
The invention relates to polymorphic markers (two tetranucleotide, one dinucleotide repeat polymorphisms, 27 markers characterized by primer pairs 1A-27A, and eleven markers characterized by primer pairs 1B-11B that are useful for human individualization. Applications are in forensic medicine and for paternity and prenatal screening as well as genetic mapping. These markers are characterized by sets of oligonucleotide primers according to the invention useful in PCR amplification and DNA segment resolution. The invention further relates to an assay for measuring the subtle differences in genetic material regarding an added or omitted set of dinucleotide or tetranucleotide repeat polymorphisms which comprises obtaining an amount of nucleotide segments effective for testing, amplifying the segments by the PCR procedure using at least one primer nucleotide sequence according to the present invention, resolving the amplified segments using gel electrophoresis, and comparing the resolved segments by autoradiography to observe the differences in migration patterns due to structural differences. The assay according to the invention is easy to perform and results can be obtained within 24 hours. It is not uncommon for results to be available within 3-4 hours.
Methods For The Treatment Of Dementia Based On Apo E Genotype
Methods For The Treatment Of Dementia Based On Apo E Genotype
US Patent:
2008021, Sep 4, 2008
Filed:
Nov 16, 2007
Appl. No.:
11/941420
Inventors:
Roger Michael Lane - New York NY, US
Mihael Hrlstos Polymeropoulos - Potomac MD, US
Mihael Hrlstos Polymeropoulos - Potomac MD, US
International Classification:
A61K 31/27, C12Q 1/68, A61P 25/00
US Classification:
514490, 435 6
Abstract:
This invention relates to methods to prevent worsening of and/or to improve cognitive functioning and behaviour problems in patients with dementia by means of ApoE genotyping to guide the use of AChEI drugs, including rivastigimine. Also included are kits for determining ApoE4 status and recommended treatment strategy.
Prediction Of Sleep Parameter And Response To Sleep-Inducing Compound Based On Per3 Vntr Genotype
Prediction Of Sleep Parameter And Response To Sleep-Inducing Compound Based On Per3 Vntr Genotype
US Patent:
2010026, Oct 14, 2010
Filed:
Sep 12, 2008
Appl. No.:
12/675614
Inventors:
Christian Lavedan - Potomac MD, US
Mihael H. Polymeropoulos - Potomac MD, US
Gunther Birznieks - Bethesda MD, US
Mihael H. Polymeropoulos - Potomac MD, US
Gunther Birznieks - Bethesda MD, US
International Classification:
A61K 31/343, G01N 33/50, C07D 307/81, A61P 25/00
US Classification:
514469, 436 94, 549462
Abstract:
The invention relates to the prediction of a sleep parameter (e.g., sleep efficiency (SE), latency to persistent sleep (LPS), wake after sleep onset (WASO), total sleep time (TST)) of an individual and the response of such an individual to a sleep inducing compound based on the individual's PER3 variable number tandem repeat (VNTR) genotype.
Methods For The Treatment Of Dementia Based On Apo E Genotype
Methods For The Treatment Of Dementia Based On Apo E Genotype
US Patent:
2010024, Sep 23, 2010
Filed:
Jun 3, 2010
Appl. No.:
12/793436
Inventors:
Roger Michael LANE - New York NY, US
Mihael Hristos Polymeropoulos - Potomac MD, US
Mihael Hristos Polymeropoulos - Potomac MD, US
International Classification:
A61K 31/27, A61P 25/16, A61P 25/00, C12Q 1/68
US Classification:
514490, 435 6
Abstract:
This invention relates to methods to prevent worsening of and/or to improve cognitive functioning and behavior problems in patients with dementia by means of ApoE genotyping to guide the use of AChEI drugs, including rivastigimine. Also included are kits for determining ApoE4 status and recommended treatment strategy.
Methods For The Administration Of Iloperidone
Methods For The Administration Of Iloperidone
US Patent:
2014004, Feb 13, 2014
Filed:
Oct 23, 2013
Appl. No.:
14/060978
Inventors:
Mihael Polymeropoulos - Potomac MD, US
Assignee:
Vanda Pharmaceuticals, Inc. - Washington DC
International Classification:
A61K 31/454
US Classification:
514321
Abstract:
The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
Methods Of Treating Psychosis And Schizphrenia Based On Polymorphisms In The Cntf Gene
Methods Of Treating Psychosis And Schizphrenia Based On Polymorphisms In The Cntf Gene
US Patent:
2008002, Jan 31, 2008
Filed:
May 29, 2007
Appl. No.:
11/754470
Inventors:
Sridhar Kudaravalli - Chicago IL, US
Mihael Polymeropoulos - Potomac MD, US
Mihael Polymeropoulos - Potomac MD, US
International Classification:
A61K 31/445, C07K 16/00, C12Q 1/68
US Classification:
514321000, 435006000, 530387100
Abstract:
This invention relates to the use of the association between the 103 G>A polymorphism in the CNTF gene to determine antipsychotic treatment strategies in patients with psychotic disorders.
Method And Composition For Treating An Alpha Adrenoceptor-Mediated Condition
Method And Composition For Treating An Alpha Adrenoceptor-Mediated Condition
US Patent:
2010027, Oct 28, 2010
Filed:
Dec 13, 2008
Appl. No.:
12/747911
Inventors:
Mihael H. Polymeropoulos - Potomac MD, US
Paolo Baroldi - Potomac MD, US
Curt D. Wolfgang - Germantown MD, US
Paolo Baroldi - Potomac MD, US
Curt D. Wolfgang - Germantown MD, US
International Classification:
A61K 31/454, A61K 31/517, A61P 9/00, A61P 9/12, A61P 5/48, A61P 3/06
US Classification:
51425217, 514321, 514284
Abstract:
Methods and compositions for the treatment of alpha-adrenoceptor mediated conditions.
Method And Composition For Treating A Serotonin Receptor-Mediated Condition
Method And Composition For Treating A Serotonin Receptor-Mediated Condition
US Patent:
8618134, Dec 31, 2013
Filed:
Dec 13, 2008
Appl. No.:
12/747912
Inventors:
Mihael H. Polymeropoulos - Potomac MD, US
Paolo Baroldi - Potomac MD, US
Curt Wolfgang - Germantown MD, US
Paolo Baroldi - Potomac MD, US
Curt Wolfgang - Germantown MD, US
Assignee:
Vanda Pharmaceuticals Inc. - Washington DC
International Classification:
A61K 31/445, A61K 31/41
US Classification:
514321, 514360
Abstract:
A method and composition for treating serotonin receptor-mediated conditions.
Cross-Reference To Related Applications
Cross-Reference To Related Applications
US Patent:
2008003, Feb 7, 2008
Filed:
Jul 22, 2005
Appl. No.:
11/572347
Inventors:
Curt Wolfgang - Germantown MD, US
Mihael Polymeropoulos - Potomac MD, US
Christian Lavedan - Potomac MD, US
Simona Volpi - Derwood MD, US
Mihael Polymeropoulos - Potomac MD, US
Christian Lavedan - Potomac MD, US
Simona Volpi - Derwood MD, US
International Classification:
A61K 31/13, A61P 27/00
US Classification:
514662000
Abstract:
Adamantane and other agents with similar effects on gene expression are useful in the treatment or prevention of ocular disorders.